2009 AHA Satellite Symposium: Can We Really Grow New Blood Vessels?

2009 Can We Really Grow New Blood Vessels?

November 15, 2009, Orlando, FL

Therapeutic angiogenesis is a novel approach to the treatment of refractory angina (RA) and critical limb ischemia (CLI). The goal of therapy is to enhance the natural process of collateral blood vessel growth through the use of growth factors, genes which encode those growth factors or stem cells. Our goal is to review the natural history of RA and CLI and to discuss current approaches to therapeutic angiogenesis. 

Agenda

Timothy D. Henry, MD, FACC
Director of Research, Minneapolis Heart Institute Foundation
Interventional Cardiologist, Minneapolis Heart Institute
Associate Professor of Medicine, University of Minnesota School of Medicine, Minneapolis
Critical Limb Ischemia: Frequency, Natural History, Available Options
Alan T. Hirsch, MD, FACC, FAHA
Director, Vascular Medicine Program, Minneapolis Heart Institute
Medical Director, Abbott Northwestern Hospital's Vascular Center
Professor of Epidemiology, University of Minnesota School of Public Health, Minneapolis
Jay H. Traverse, MD, FACC, FAHA
Interventional Cardiologist, Minneapolis Heart Institute
Associate Professor of Medicine, University of Minnesota School of Medicine, Minneapolis
CD34+ Stem Cells for Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Douglas W. Losordo, MD, FAHA, FACC
Director, Feinberg Cardiovascular Research Institute and Program in Cardiovascular Regenerative Medicine
Northwestern Memorial Hospital, Chicago, Illinois
Christopher J. White, MD, FACC, FAHA
Director, Ochsner Heart and Vascular Institute
Chairman, Department of Cardiology
New Orleans, Louisiana
Subhash Thakur, MD
Vascular Surgeon
Jobst Vascular Center
Toledo, Ohio
Gene Therapy for Critical Limb Ischemia
Sigrid Nikol, MD
Head of Clinical and Interventional Angiology
ASKLEPIOS Klinik St. Georg
Hamburg, Germany
Timothy D. Henry, MD, FACC
Director of Research, Minneapolis Heart Institute Foundation
Interventional Cardiologist, Minneapolis Heart Institute
Associate Professor of Medicine, University of Minnesota School of Medicine, Minneapolis

After attending this symposium, participants will be able to:

1.   Describe the natural history and prevalence of refractory angina (RA) and critical limb ischemia (CLI).

2.   Discuss the current available clinical and research options for RA and CLI, including revascularization, pharmacological, cell and angiogenic therapies.

3.   Explain the rationale and trial results of cell and angiogenic therapies in RA and CLI.